Aug 8, 2023
Featured article on NoCamels
ExoProTher's groundbreaking approach to cancer treatment has gained well-deserved recognition with a featured article on NoCamels, a leading source of Israeli innovative technology and science news. Titled "Revolutionary Protein-Based Cancer Drug Targets Tumors Without Harming Healthy Cells," the article highlights ExoProTher's achievement in developing a protein-based cancer drug that demonstrates an exceptional ability to selectively target cancerous cells while sparing healthy ones.
The featured interview with Lana Volokh, CEO and Alex Tendler, CTO of ExoProTher’s presents our unique approach to cancer therapy.
The article further highlights ExoProTher's commitment to revolutionizing cancer therapy and impacting cancer patients' lives.
Apr 19, 2023
ExoProTher at AACR ANNUAL MEETING 2023
ExoProTher's CTO Presents Breakthrough Finding on Chicken p53 Efficacy Against Human Cancers
Orlando, Florida — April 19, 2023 — Dr. Alex Tendler, Chief Technology Officer of ExoProTher Medical, participated in the AACR Annual Meeting 2023 that took place in Orlando, Florida. Dr. Tendler unveiled a scientific poster summarizing a year of progress in research and development.
The highlight of the presentation was ExoProTher's groundbreaking discovery: the efficacy of chicken p53 in combating human cancer. This result holds immense promise for innovative therapies and advances our understanding of cancer mechanisms. Presented results showcased successful outcomes across a variety of human cancer cell line in vitro, including GBM, colon, ovarian, and lung cancers.
"Our presence at AACR reaffirms ExoProTher's commitment to pushing medical boundaries," said Dr. Tendler. "The potential of chicken p53 in human cancer cells opens new doors in our fight against cancer."
Engaging with thought leaders across various fields, ExoProTher harnessed the AACR Annual Meeting to enrich its perspective and fuel future research endeavors.
Jan 4, 2023
ExoProTher Podcast - OutcomesRocket
The origin of our anti-cancer treatment - ExoProTher Medical on OutcomesRocket
30 seconds about the origin of our anti-cancer treatment.
Dec 30, 2021
Israel Biotech Fund
We are excited to step into 2022 together with IBF
Proud to be part of exclusive portfolio of innovative #lifesciences companies.
This funding accelerates the path towards clinical stage of our first-in-class biotherapy targeting cancers with p53 mutations.
We are on mission to bring cure to cancer patients.
Dec 11, 2021
Virtual MedInvest Oncology Investor Conference
This week ExoProTher Medical presented at the virtual MedInvest Oncology Investor Conference. ExoProTher’s Chief Executive Officer, Lana Volokh, delivered the corporate overview. She described the Company’s unique scientific foundation and technology and provided an update on program status. ExoProTher aims to significantly impact the way cancer is treated. Link to the presentation recording: https://youtu.be/JxwwiSTyrwk
Jun 23, 2021
New R&D lab at Colab Square Facility, Yokneam
Beginning May 2021, ExoProTher is operating a new R&D lab situated at unique Colab Square facility in Yokneam Industrial park. ExoProTher is joining a line of exciting and promising biotech companies.
The combination of location, equipment and environment allow to boost R&D activities and attract top talent to the expanding team.
Nov 11, 2020
ExoProTher milestone achieved
I am pleased to share with our followers and investors the latest in vivo results.
Two weeks ago, a successful in vivo experiment on mouse model of colon cancer ended with impressive results. Life span of treated mice was significantly prolonged after single dose of Exo, while 25% of them remained tumor-free after the experiment completion. Additional in vivo studies using other cancer models are in progress.
Lana Volokh - CEO
Sep 12, 2020
New recruits & Additional facility
Exciting growth period for ExoProTher Medical: we opened a new laboratory facility and brought on board new talent.
The new laboratory started functioning in Shlomi, Israel. It will focus on optimizing production and characterization of EXO_ compounds.
With extended R&D team, we continue to broaden and deepen our research capabilities.
Dec 1, 2019
ExitValley's Investors meeting
What a great event to be part of – first ExitValley’s Investors meeting!
Dr. Alex Tendler, co-founder and CTO of ExoProTher Medical, presented our unique concept and its outstanding potential to the very interested audience.
ExoProTher Medical launched the crowdfunding campaign using ExitValley platform.
It is super cool to see first investment after less than 12 hours. Amazing start.